Takeda Pharmaceutical Co (0RN3) Ownership - Who Owns Takeda Pharmaceutical Co?
Takeda Pharmaceutical Co (0RN3) Ownership Overview
- 0.19% Insiders
- 9.18% Mutual Funds
- <0.01% Other Institutional Investors
- 15.79% ETFs
- 74.84% Public Companies and Individual Investors
The ownership structure of Takeda Pharmaceutical Co (GB:0RN3) stock is a mix of institutional, retail, and individual investors. Approximately 24.97% of the company’s stock is owned by Institutional Investors, 0.19% is owned by Insiders, and 74.84% is owned by Public Companies and Individual Investors.
The ownership structure of Takeda Pharmaceutical Co (GB:0RN3) stock is a mix of institutional, retail, and individual investors. Approximately 24.97% of the company’s stock is owned by Institutional Investors, 0.19% is owned by Insiders, and 74.84% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Sep 14, 2026 | Lauren Duprey | $640,297 | |
| Sep 02, 2026 | Plump Andrew | $2,148,353 | |
| Aug 20, 2026 | Plump Andrew | $363,329 | |
| Aug 18, 2026 | Nicola Deidre Petal Greenway | $235,118 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Ishares | 76,427,297 | Institution | 4.77% | 3,014,598,303 |
| Vanguard | 58,497,285 | Institution | 3.65% | 2,307,366,910 |
| Ubs | 26,209,668 | Institution | 1.64% | 1,033,814,145 |
| Vanguard Star Funds | 23,301,746 | Institution | 1.45% | 919,114,069 |
| Xtrackers | 21,262,313 | Institution | 1.33% | 838,670,674 |
| Vanguard Tax-managed Funds | 15,464,832 | Institution | 0.97% | 609,994,833 |
| Amundi | 15,339,800 | Institution | 0.96% | 605,063,071 |
| Jpmorgan | 13,918,866 | Institution | 0.87% | 549,015,751 |
| Capital World Growth & Income Fund | 13,243,091 | Institution | 0.83% | 522,360,481 |
| Capital Income Builder | 10,077,550 | Institution | 0.63% | 397,498,882 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Star Funds | 23,301,746 | Institution | 1.45% | 919,114,069 |
| Vanguard Tax-managed Funds | 15,464,832 | Institution | 0.97% | 609,994,833 |
| Capital World Growth & Income Fund | 13,243,091 | Institution | 0.83% | 522,360,481 |
| Capital Income Builder | 10,077,550 | Institution | 0.63% | 397,498,882 |
| Fidelity Investment Trust | 8,505,664 | Institution | 0.53% | 335,497,411 |
| T. Rowe Price International Funds, Inc. | 8,347,700 | Institution | 0.52% | 329,266,679 |
| Fidelity Rutland Square Trust Ii | 8,133,148 | Institution | 0.51% | 320,803,890 |
| Fidelity Salem Street Trust | 7,755,946 | Institution | 0.48% | 305,925,534 |
| Fidelity Concord Street Trust | 6,987,907 | Institution | 0.44% | 275,631,004 |
| Vanguard International Equity Index Funds | 6,747,535 | Institution | 0.42% | 266,149,771 |
FAQ
Who Owns Takeda Pharmaceutical Co (GB:0RN3)?
According to the latest TipRanks data, approximately 24.97% of the company's stock is held by institutional investors, 0.19% is held by insiders, and 74.84% is held by public companies and individual investors.
What percentage of Takeda Pharmaceutical Co (GB:0RN3) stock is held by institutional investors?
According to the latest TipRanks data, approximately 24.97% of Takeda Pharmaceutical Co (GB:0RN3) stock is held by institutional investors: 9.18% by mutual funds, 15.79% by ETFs and <0.01% by other institutional investors.
What percentage of Takeda Pharmaceutical Co (GB:0RN3) stock is held by retail investors?
According to the latest TipRanks data, approximately 74.84% of Takeda Pharmaceutical Co (GB:0RN3) stock is held by public companies and individual investors.
Who owns the most shares of Takeda Pharmaceutical Co (GB:0RN3)?
iShares owns the most shares of Takeda Pharmaceutical Co (GB:0RN3).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.